Company

Projects

Competence Centre of Pharmaceutical, Biomedical and Medical Technology

Operational Program ‘Growth and Jobs’ 1.2.1. Specific objective 1.2.1.1 “Increase private sector investment in R&D”. event “Support for development of new products and technologies within centers of excellence”

From June 1, 2016 until December 31, 2018, within the measure “Development of New Products And Technologies within the Competence Centre” of the Specific Support aim No. 1.2.1 “Increase Private Sector Investment in R&D” of the Operational programme “Growth and Employment” the Competence Centre of Pharmaceutical, Biomedical and Medical Technology Ltd. (SIA “Farmācijas, biomedicīnas un medicīnas tehnoloģiju Kompetences centrs”) implements the project No. 1.2.1.1/16/A/006 “Competence Centre of Pharmaceutical, Biomedical and Medical Technology”.

The founders of the Competence Centre of Pharmaceutical, Biomedical and Medical Technology Ltd. are the five leading pharmaceutical, chemical and cosmetic companies in Latvia: AS “Olainfarm”, AS “Grindeks”, SIA “PharmIdea”, SIA “LabochemLV”, SIA “Madara Cosmetics” and the Association of the Latvian Chemical and Pharmaceutical Industry. For more information see http://fbmtkc.lv/.

Competence Centre of Pharmaceutical, Biomedical and Medical Technology covers two scientific directions:

  1. Pharmacy, Original Medicine, and Generic Medicine – the study of active substances for developing new medicines, incl., generic medicines, evaluation of specific substances for the treatment of certain diseases, etc.;
  2. Natural substance medicine, nutritional supplements, functional cosmetics – to develop new cosmetic products according to the trends of the cosmetics industry.

The aim of the Competence Centre is to support at least 12 studies according to the predefined study direction to develop new products and technologies for the industry, as well as to implement them into production, thus promoting the cooperation between research and manufacturing industries, as well as increasing the competitiveness of the industry. The total ERDF funding for the project is estimated at EUR 3,206,250.00.

On 1 September, 2016, SIA SILVANOLS has started the implementation of the study project “Development of a natural substance-based anti-allergy prophylaxis medical device as well as product quality, safety, and efficiency studies” (P4) within the project “Competence Centre of Pharmaceutical, Biomedical and Medical Technology”. The aim of the study project is to develop a new product using natural plant substances that have the capability to suppress symptoms caused by allergic reactions without causing unwanted side effects to the user.

The project is planned to be implemented by December 31, 2018. The total cost of the project is EUR 219,184.00, including EUR 95,893.00 from the European Regional Development Fund. Chronology of the works carried out within the study project of SIA SILVANOLS – “Development of a natural substance-based anti-allergy prophylaxis medical device as well as product quality, safety and efficiency studies” (P4) of the project “Competence Centre of Pharmaceutical, Biomedical and Medical Technology”:

  1. From September 2016 to November 2017 SIA SILVANOLS organised several procurement procedures: “Study of the Physical Layering Properties and Effects of Tissue Viability of Medical Device Samples”, “In vitro Study on Effective Dose of Medical Device Samples” and “In vivo Study on Physical Exposure of Medical Device Samples”. The total contract price offered as a result of the procurement is EUR 106,530.00. Information on procurements announced and its results is available on the Procurement Monitoring Bureau’s website: www.iub.gov.lv.
  2. On February 21, 2017 the company SIA “Farmācijas, biomedicīnas un medicīnas tehnoloģiju Kompetences centrs” (Competence Centre of Pharmaceutical, Biomedical and Medical Technology) has received a payment from the European Regional Development Fund for payment request No.1 for the period: 01/06–10/10/2016 with eligible costs of SIA SILVANOLS studies amounting to EUR 2,912.42, including European Regional Development Fund financing of EUR 1,456.22.
  3. On March 30, 2017 the company SIA “Farmācijas, biomedicīnas un medicīnas tehnoloģiju Kompetences centrs” (Competence Centre of Pharmaceutical, Biomedical and Medical Technology) has received a payment from the European Regional Development Fund for payment request No. 2 for the period: 11/10/2016–10/01/2017 with eligible costs of SIA SILVANOLS studies amounting to EUR 11,494.67, including European Regional Development Fund financing of EUR 5,747.34.
  4. On August 18, 2017 the company SIA “Farmācijas, biomedicīnas un medicīnas tehnoloģiju Kompetences centrs” (Competence Centre of Pharmaceutical, Biomedical and Medical Technology) has received a payment from the European Regional Development Fund for payment request No. 3 for the period: 11/01/2017–10/04/2017 with eligible costs of SIA SILVANOLS studies amounting to EUR 16,483.75, including European Regional Development Fund financing of EUR 8,241.88.
  5. On October 2, 2017 the company SIA “Farmācijas, biomedicīnas un medicīnas tehnoloģiju Kompetences centrs” (Competence Centre of Pharmaceutical, Biomedical and Medical Technology) has received a payment from the European Regional Development Fund for payment request No. 4 for the period: 11/04/2017–10/07/2017 with eligible costs of SIA SILVANOLS studies amounting to EUR 21,353.15, including European Regional Development Fund financing of EUR 10,676.58.
  6. On January 23, 2018 the company SIA “Farmācijas, biomedicīnas un medicīnas tehnoloģiju Kompetences centrs” (Competence Centre of Pharmaceutical, Biomedical and Medical Technology) has received a payment from the European Regional Development Fund for payment request No. 5 for the period: 11/07/2017–10/10/2017 with eligible costs of SIA SILVANOLS studies amounting to EUR 19,344.90, including European Regional Development Fund financing of EUR 9,672.45.
  7. On April 26, 2018 the company SIA “Farmācijas, biomedicīnas un medicīnas tehnoloģiju Kompetences centrs” (Competence Centre of Pharmaceutical, Biomedical and Medical Technology) has received a payment from the European Regional Development Fund for payment request No. 6 for the period: 11/10/2017–10/01/2018 with eligible costs of SIA SILVANOLS studies amounting to EUR 26,777.06, including European Regional Development Fund financing of EUR 13,388.46.
  8. On July 17, 2018 the company SIA “Farmācijas, biomedicīnas un medicīnas tehnoloģiju Kompetences centrs” (Competence Centre of Pharmaceutical, Biomedical and Medical Technology) has received a payment from the European Regional Development Fund for payment request No. 7 for the period: 11/01/2018–10/04/2018 with eligible costs of SIA SILVANOLS studies amounting to EUR 45,997.16, including European Regional Development Fund financing of EUR 21,046.15.
  9. On October 3, 2018 the company SIA “Farmācijas, biomedicīnas un medicīnas tehnoloģiju Kompetences centrs” (Competence Centre of Pharmaceutical, Biomedical and Medical Technology) has received a payment from the European Regional Development Fund for payment request No. 8 for the period: 11/04/2018–10/07/2018 with eligible costs of SIA SILVANOLS studies amounting to EUR 3,752.01, including European Regional Development Fund financing of EUR 1,849.93.
  10. On October 17, 2018, the company SIA “Farmācijas, biomedicīnas un medicīnas tehnoloģiju Kompetences centrs” (Competence Centre of Pharmaceutical, Biomedical and Medical Technology) submitted a report and a payment request No. 9 on the activities carried out within the framework of the project, the results achieved and the expenditure incurred for the accounting period of 11/07/2018–10/10/2018.
  11. At the beginning of November 2018, an outsourcing contract amounting to EUR 31,250.00 was concluded within the framework of the market research to study the anti-allergic spray component coating properties.
  12. On December 31, 2018, the project was completed. As planned, within the framework of the project, a new natural substance-based anti-allergy prevention product prototype with medical device status has been developed.
  13. In January 2019, the company SIA “Farmācijas, biomedicīnas un medicīnas tehnoloģiju Kompetences centrs” (Competence Centre of Pharmaceutical, Biomedical and Medical Technology) submitted a final report on the activities carried out within the framework of the project, the results achieved and the expenditure incurred for the accounting period of 11/10/2018–31/12/2018.

 

Share this...
Share on Facebook
Facebook
Share on LinkedIn
Linkedin
Back to top